Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Presents Primate Data on Subcutaneous Cholesterol Drug

Premium

Alnylam Pharmaceuticals this week released new preclinical data showing that its subcutaneously delivered hypercholesterolemia drug ALN-PCSsc could knock its target down by as much as 95 percent and decrease low-density lipoprotein levels by up to 67 percent in non-human primates.

ALN-PCSsc is preclinical a version of Alnylam's phase II intravenously delivered drug ALN-PCS, which targets proprotein convertase subtilisin/kexin type 9. Earlier this year, The Medicines Company acquired the rights to develop and commercialize both agents after phase II testing.

"Our new study results in non-human primates show an up to 95 percent knockdown of plasma PCSK9 and an up to 67 percent reduction of LDL-C in the absence of statin co-administration, with a very durable knockdown of more than 50 days after the last dose," Alnylam's Vice President of Research Rachel Meyers said in a statement. "We believe these results support a highly competitive target product profile, and we look forward to advancing ALN-PCSsc toward clinical trials in 2014 with our partner The Medicines Company."

The data were presented at this year's American Heart Association Scientific Sessions.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.